Wall Street analysts forecast that Nabriva Therapeutics (NASDAQ:NBRV) will announce sales of $1.27 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Nabriva Therapeutics’ earnings. The lowest sales estimate is $1.00 million and the highest is $1.70 million. Nabriva Therapeutics posted sales of $1.68 million in the same quarter last year, which suggests a negative year-over-year growth rate of 24.4%. The business is scheduled to issue its next earnings report on Wednesday, May 9th.
On average, analysts expect that Nabriva Therapeutics will report full year sales of $5.06 million for the current fiscal year, with estimates ranging from $2.90 million to $7.40 million. For the next year, analysts anticipate that the business will report sales of $11.12 million per share, with estimates ranging from $8.81 million to $15.17 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Friday, March 16th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.06). The business had revenue of $1.12 million during the quarter, compared to analyst estimates of $1.37 million. Nabriva Therapeutics had a negative return on equity of 88.66% and a negative net margin of 1,370.53%.
Several research firms have issued reports on NBRV. Wedbush restated an “outperform” rating on shares of Nabriva Therapeutics in a research report on Monday, March 19th. ValuEngine upgraded shares of Nabriva Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. Zacks Investment Research cut shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. Bank of America began coverage on shares of Nabriva Therapeutics in a research report on Wednesday, March 21st. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Morgan Stanley began coverage on shares of Nabriva Therapeutics in a research report on Wednesday, January 17th. They set an “overweight” rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $16.69.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. purchased a new position in shares of Nabriva Therapeutics during the 3rd quarter valued at $5,724,000. Jane Street Group LLC purchased a new position in shares of Nabriva Therapeutics during the 3rd quarter valued at $293,000. Cubist Systematic Strategies LLC purchased a new position in shares of Nabriva Therapeutics during the 3rd quarter valued at $348,000. Pura Vida Investments LLC purchased a new position in shares of Nabriva Therapeutics during the 3rd quarter valued at $3,481,000. Finally, Rubric Capital Management LP purchased a new position in shares of Nabriva Therapeutics during the 3rd quarter valued at $2,457,000. Hedge funds and other institutional investors own 55.56% of the company’s stock.
Nabriva Therapeutics stock traded down $0.07 during mid-day trading on Thursday, hitting $4.91. The company’s stock had a trading volume of 244,764 shares, compared to its average volume of 415,185. The firm has a market cap of $182.85, a price-to-earnings ratio of -1.97 and a beta of 1.77. Nabriva Therapeutics has a twelve month low of $4.39 and a twelve month high of $14.10.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Nabriva Therapeutics (NBRV) Will Announce Quarterly Sales of $1.27 Million” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/15/zacks-brokerages-anticipate-nabriva-therapeutics-nbrv-will-announce-quarterly-sales-of-1-27-million.html.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.
Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.